After tumor establishment (>15 mm2, day 10 post inoculation), tumor-bearing mice were treated with PBS or chemotherapy (FOLFOX) once a week for 3 weeks. The dose given was: 5-Fu (100 mg/kg) and Oxa (2.5 mg/kg). Leucovorin was omitted as this adds marginal effectiveness to 5-FU but can significantly increase toxicity in murine subjects. The drugs were diluted in 100 μl PBS and given i.p. These doses are adopted from previous studies (23 (link), 29 (link)) and are within the range (mg/Kg) used in the clinic for humans. For anti-PD-1 treatment, when tumors were established (~40 mm2, day 14 post inoculation), animals were assigned to treatment groups. Anti-PD-1 treatment was initiated with FOLFOX on the same day. Mice were treated with i.p. injection of anti-PD-1 (RMP1-14, BioXcell) or control antibody (clone 2A3, BioXcell) at 200 μg per mouse for a total of 6 doses every 3 days. FOLFOX was given once a week as described above. Tumor dimensions were measured and monitored every 2–3 days until endpoints.
Control antibody clone 2a3
Manufactured by BioXCell
Sourced in United States
The Control antibody (clone 2A3) is a research tool used in various laboratory applications. It functions as a control antibody, providing a baseline for comparison in experiments involving antibody-based techniques.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using control antibody clone 2a3
1
Evaluating FOLFOX and Anti-PD-1 in Murine Tumors
2
Passaging MC38 Tumor Models in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
C57BL/6J mice bearing MC38 tumors were treated with 5 mg/kg anti-PD-1 antibody (clone RMP1-14, BioXCell, West Lebanon, NH, USA) or control antibody (clone 2A3, BioXCell) twice weekly by intraperitoneal (i.p.) injection. Tumors selected for passaging were excised, dissociated using a mouse tumor dissociation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured in vitro until implantation into naïve mice. This process was repeated for a total of three rounds of passaging, with anti-PD-1 antibody dose increased to 10 mg/kg for the second and third rounds.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!